Survodutide: The GLP-1/Glucagon Dual Agonist Redefining Metabolic Research

Survodutide (BI 456906, Boehringer Ingelheim) is a once-weekly injectable dual GLP-1/glucagon receptor agonist. Unlike tirzepatide (GLP-1/GIP) and retatrutide (GLP-1/GIP/glucagon), survodutide's combination of GLP-1 with glucagon — without GIP — creates a distinct metabolic signature. This profile has positioned survodutide as a leading compound for non-alcoholic steatohepatitis (NASH/MASH) and visceral fat research, where glucagon's hepatic metabolic actions are particularly relevant.

Mechanism: GLP-1 + Glucagon Without GIP

Survodutide co-activates two receptors with complementary metabolic roles:

• GLP-1 receptor: Central appetite suppression, delayed gastric emptying, glucose-dependent insulin secretion, cardiovascular protection signals.
• Glucagon receptor: Hepatic fat oxidation (β-oxidation upregulation), increased energy expenditure (thermogenesis), visceral adipose tissue mobilisation, and bile acid modulation.

The absence of GIP receptor agonism distinguishes survodutide from tirzepatide. GIP contributes to adipose insulin sensitisation and potentially to a more favourable GI tolerability profile in tirzepatide. Survodutide's GIP-free approach means its tolerability profile may differ, but its glucagon-enhanced hepatic activity may be superior for liver-specific metabolic endpoints.

NASH/MASH Research Data

Survodutide has received specific attention for NASH (metabolic dysfunction-associated steatohepatitis) research — an area where glucagon receptor activation's hepatic fat oxidation mechanism is mechanistically compelling. Phase 2b NASH trial data showed:

• Significant reduction in liver fat (MRI-PDFF) at 6 months versus placebo
• Improvement in NASH resolution rates (biopsy-confirmed) in higher-dose arms
• Reduction in fibrosis markers (ALT, AST, APRI)
• Beneficial effects on hepatic steatosis greater than weight loss alone would predict — suggesting a direct glucagon-mediated hepatic mechanism beyond indirect effects of weight reduction

This liver-specific data differentiates survodutide from tirzepatide, which has less dedicated NASH data. For researchers studying liver metabolic disease, survodutide's mechanistic and clinical profile makes it the more targeted choice.

Weight Loss Efficacy

Phase 2 obesity trial data for survodutide showed weight reductions of approximately 14–18% at optimal doses over 46 weeks. While this is lower than retatrutide's 24.2% in Phase 2 data, survodutide's weight loss is comparable to semaglutide and provides the added hepatic and visceral fat benefits of glucagon agonism. The compound is progressing through Phase 3 obesity and NASH trials.

Comparison to Retatrutide and Tirzepatide

• vs Retatrutide: Retatrutide adds GIP to the GLP-1/glucagon combination, achieving greater weight loss. Survodutide's value proposition is a more liver-specific profile and potentially being the superior choice for dedicated NASH studies.
• vs Tirzepatide: Tirzepatide uses GLP-1/GIP without glucagon, showing superior insulin sensitisation and body weight reduction compared to semaglutide. Survodutide's glucagon component provides hepatic and energy expenditure advantages that tirzepatide lacks.

Side Effect Profile

Survodutide shares the GLP-1 class GI adverse event profile (nausea, vomiting, diarrhoea). The glucagon component may contribute to slightly higher nausea rates compared to pure GLP-1 agonists. Dose-dependent GI events are manageable with slow titration schedules. No unique safety signals beyond the GLP-1/glucagon class have emerged in Phase 2 data.

Frequently Asked Questions

Why is survodutide particularly interesting for NASH research?

The glucagon receptor component drives hepatic fat oxidation through mechanisms independent of weight loss alone — this direct hepatic metabolic activity makes survodutide mechanistically well-suited for fatty liver disease research beyond what appetite suppression alone would achieve.

How does survodutide differ from semaglutide for liver disease?

Semaglutide shows weight loss benefits and some liver fat reduction, but its GLP-1-only mechanism lacks the direct hepatic glucagon receptor activation that drives survodutide's more pronounced liver-specific effects in early trial data.

References

• Newsome PN, et al. (2023). Survodutide for MASH: Phase 2b trial results. NEJM Evidence.
• Sanyal AJ, et al. (2024). Survodutide in metabolic dysfunction-associated steatohepatitis. The Lancet.
• Jastreboff AM, et al. (2023). Triple–Hormone-Receptor Agonist Retatrutide for Obesity. New England Journal of Medicine, 389, 514–526.